MDS Current Trials UK

We aim to list an easily understandable description of any MDS clinical trials currently opened to recruitment in the UK.

Patients will be able to read up on the details of these trials and use this information to discuss with their consultants or nurses. If you'd like more information about what a clinical trial is and how it is conducted, please go to this section or download our Clinical Trials factsheet.

Not all patients can be enrolled in drug trials - as not every patient will fit the necessary inclusion criteria, which need to be followed very strictly. However, if a particular clinical trial drug is considered an option by the haematologist, it is sometimes possible to obtain the drug outside the trial, on the basis of compassionate use.

In addition, here you will find a list of clinical trials which are still running but are closed to recruitment. 

All the trials listed in this page have been properly vetted for scientific accuracy. Many thanks to Dr Simone Green – Hull and East Yorkshire Hospitals NHS Trust - for her continuous work in updating this listing.

Learn more about the latest MDS research

MDS Clinical Trials


  1. SUB-TYPE OF MDS: All subtypes of MDS.
  2. SEVERITY OF MDS: High Risk MDS and Acute myeloid leukaemia.
  3. NAME OF DRUG: CCS-1477
    1. Read full story


  1. SUB-TYPE OF MDS: All Subtypes
  2. SEVERITY OF MDS: Intermediate, High or Very High Risk
  3. NAME OF DRUG: Venetoclax
    1. Read full story


  1. SUB-TYPE OF MDS: Patients with relapsed/refractory AML or AML secondary to myeloproliferative neoplasm.
  2. SEVERITY OF MDS: Intermediate, High or Very High Risk
  3. NAME OF DRUG: KRT-232
    1. Read full story

UCART123 – Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS:Patients newly diagnosed with CD123 positive adverse genetic risk acute myeloid leukaemia (AML), including patients with CD123 positive AML secondary to MDS
  3. NAME OF DRUG: UCART targeting CD123 positive leukaemia cells
Read full story

RFUSIN2-AML1 – Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS:Patients AML (acute myeloid leukaemia) who fail to enter morphological remission or have persistence of cytogenetic abnormality following intensive combination chemotherapy at day+100 post-transplant
  3. NAME OF DRUG: Lentivirus Transduced Acute Myeloid Leukaemic Cells (AML) that express
    B7.1 (CD80) and IL-2 (AML cell vaccine)
Read full story
Free donations by shopping

Sign-up to Download our Free Patient Handbook!

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

MDS UK Patient Support Group will use the information you provide on this form to be in touch with you and to provide updates.